Section 1: CKD Epidemiology

Slides:



Advertisements
Similar presentations
Risk Stratification in Renal Care Mary Jane McKendry Vice President, Operations Fresenius Disease Management Optimal Renal Care.
Advertisements

The National Kidney Foundations Kidney Early Evaluation Program TM The National Kidney Foundations Kidney Early Evaluation Program TM Essex-Passaic Wellness.
Chronic kidney disease: [insert title here] Insert name, title, date here Insert acknowledgements here.
Recent Advances in Management of CRF Yousef Boobess, M.D. Head, Nephrology Division Tawam Hospital.
DEVELOPMENT OF STRATEGIES FOR PREVENTION OF CHRONIC KIDNEY DISEASE RELEVENT TO DIFFERENT REGIONS AND COUNTRIES ROBERT C ATKINS BELLAGIO, MARCH 2004.
Lesley Stevens MD Tufts-New England Medical Center
Prevalance of Chronic Kidney Disease 26 million people have diagnosed chronic kidney 26 million people have diagnosed chronic kidney disease (CKD) ( National.
Section 1: CKD Epidemiology. The Problem Chronic Kidney Disease is an epidemic worldwide –Growth 6-8% per annum of dialysis patients Accumulating data.
Early Detection and Prevention of Renal Failure Linda Fried, MD, MPH.
RENAL DISEASE IN DIABETES
SM Gatmiri, MD, Nephrologist Imam Khomeini Hospital,
UKRR Annual Informatics Meeting, September 2013 Highlights from the 15 th Annual Report Rishi Pruthi Research Fellow UK Renal Registry.
Section 6: Management in primary care Particular emphasis on nurse practitioner’s role.
If I had Chronic Kidney Disease: What would I want my Doctor to Know….. Liam Plant Department of Renal Medicine, Cork University Hospital Department of.
The management of renal problems in primary care Hugh Gallagher Consultant Nephrologist St Helier Hospital.
These slides were sponsored by Janssen and developed in conjunction with the BRS CKD Strategy Group, following an advisory board that was organised by.
Section 5: Configuration of healthcare to manage CKD.
Section 2: Detection of CKD. What Tests Are Available? Direct GFR measurement –Inulin clearance –Radionuclides –Iohexol clearance 3 hr CrCl with Cimetidine.
Dr M Sivalingam Renal Unit, Lister Hospital, Stevenage.
Healthy People 2010 Focus Area 4
Highlights from the Annual Report UK Renal Registry 2013 Annual Audit Meeting Dr Catriona Shaw Registrar, UK Renal Registry.
Summary of the 2013 ERA-EDTA Registry Annual Report Amsterdam, the Netherlands, 2015.
The Databases: Successes and Shortcomings in Renal Replacement Therapy Since 1989 European Renal Association and European Dialysis and Transplant Association.
CHRONIC KIDNEY DISEASE
Chronic Kidney Disease (CKD) Healthy Kansans 2010.
1 به نام خدا. Epidemiology of chronic kidney disease 2.
Sheffield Kidney Institute Global Kidney Academy CKD Micro-Lecture Epidemiology, Screening and Guidelines Professor Meguid El Nahas, PhD, FRCP Sheffield.
Chronic Kidney Disease (CKD) Dr. Sham Sunder. Now we know why the titanic sank !! < 0.5 % 5- 10%
USRDS USRDS 2002 adr Incident counts by initial modality figure 7.1 patients age 19 years & younger.
2016 Annual Data Report, Vol 2, ESRD, Ch 13
2016 Annual Data Report, Vol 2, ESRD, Ch 5
National service framework for Renal
Section 2: Detection of CKD
UK Renal Registry 13th Annual Report
Figure 1.1 Prevalence of CKD by stage among NHANES participants,
Section 4: Managing progression of CKD
Section 6: Management in primary care
Golden Rules to Keep Kidneys Healthy
Copyright © 2015 by the American Osteopathic Association.
Odd ratio of developing kidney failure figure 1
ASSIST CKD: Scaling up an intervention to improve the management of progressive chronic kidney disease.
Lead for the quantitative evaluation
ANZDATA Registry 39th Annual Report Chapter 13: End Stage Kidney Disease in Aotearoa/New Zealand Data to 31-Dec-2015.
Section 3: CKD, CVD and mortality
2017 Annual Data Report Healthy People 2020.
Summary of the 2013 ERA-EDTA Registry Annual Report
Volume 2: End-Stage Renal Disease Chapter 4: Hospitalization
Chapter 1: CKD in the General Population
December 31st point prevalent counts by modality figure 3.1
Test.
The IDEAL Study Reference
UK Renal Registry 9th Annual Report 2006
UK Renal Registry 10th Annual Report 2007
Chronic Kidney Disease in HIV Infection: An Urban Epidemic
Volume 2: End-Stage Renal Disease Chapter 4: Hospitalization
Renal Pharmacy Group Beginners Lectures 2018
2018 Annual Data Report Volume 3: Healthy People 2020
Chapter 1: CKD in the General Population
به نام خدا.
CHAPTER 1 All Renal Replacement Therapy In Malaysia
Section 5: Configuration of healthcare to manage CKD
Meeting the challenges of the new K/DOQI guidelines
UK Renal Registry 16th Annual Report
Reported ESRD Period and Point Prevalence,
ASSIST CKD: Scaling up an intervention to improve the management of progressive chronic kidney disease.
American Journal of Kidney Diseases
UK Renal Registry 15th Annual Report
ASSIST CKD: Scaling up an intervention to improve the management of progressive chronic kidney disease.
Lynda Anne Szczech, Ira L. Lazar  Kidney International 
Worldwide incidence of ESRD figure 12.1, per million population
Presentation transcript:

Section 1: CKD Epidemiology

The Problem Chronic Kidney Disease is an epidemic worldwide Growth 6-8% per annum of dialysis patients Accumulating data re: possibility of delaying the progression of kidney disease, using multiple drug and behaviour intervention therapies. Under-recognition at earlier stages of kidney dysfunction persists Late referral Lost opportunities for improved patient outcomes  

RRT Modalities 36,542 DOD/0503-04

Age Specific Rate per Million Patients Accepted in the UK for Renal Replacement Therapy 50 100 150 200 250 300 80 81 82 83 84 85 86 87 88 90 91 92 93 94 95 96 97 98 99 2000 2001 Year Age Specific Rate per Million 0 - 44 45 - 64 65+ Diabetics Total

Cadaveric Kidney Donors & Transplants and End of Year Kidney Waiting List, UK, 1994-2003 DOD/0503-04

Prevalence of renal replacement therapy Take-on rates /pmp England 98 Wales 118 France 200 Italy 260 USA 315

Estimates of Prevalence of CKD in the US: NHANES III Stage Description GFR (ml/min/1.73 m2) Prevalence (000s) (%) 1 Kidney Damage with Normal or  GFR >90 5,900 3.3 2 Kidney Damage with Mild  GFR 60-89 5,300 3.0 3 Moderate  GFR 30-59 7,600 4.3 4 Severe  GFR 15-29 400 0.2 5 Kidney Failure <15 or (or dialysis) 300 0.1 Using their definition and classification of stages of chronic kidney disease the K/DOQI workgroup was able to provide rough estimates of the prevalence of each stage in adults aged 20 or over from the Third National Health and Nutrition Examination Survey (NHANES III) in the United States. In the United States, there is a rising incidence and prevalence of kidney failure. There is an even higher prevalence of earlier stages of CKD. Adapted from Am J Kidney Dis 2002; 39 (2, Suppl. 1): S17-S31

NICE: 2008 Classification of CKD waking up to the impact of proteinuria Stage 1: GFR>90 + abnormal urinalysis Stage 2: GFR 60-89 + abnormal urinalysis Stage 3A: GFR 45-59 Stage 3B: GFR 30-44 Stage 4: GFR 15-29 Stage 5: GFR <15 or dialysis dependent Suffix P denotes presence of proteinuria (ACR>30 or PCR>50)

National Disease Prevalence Survey (%)

CKD: A Typical GP Practice of 10000 5 6 15 4 60 Stage of Kidney Disease 30 (GFR) 380 3 60 2 460 90 1

Incident Rates by Primary Diagnosis (per million population, unadjusted) Diabetes is the most rapidly rising cause of ESRD, but hypertension and glomerulonephritis rates also continue to rise. USRDS, 2000

Obesity Trends: UK

Life expectancy: UK